| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
AdCLD-CoV19 is aCOVID-19 vaccine candidate developed by Cellid Co,[2][3] a company from South Korea.[4]
A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[5] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[6]Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[7] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[8]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
